Eicosanoids and Arrhythmogenesis

  • J. R. Parratt
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 89)

Abstract

Most standard approaches to antiarrhythmic therapy, for example in myocardial ischaemia, involve the administration of synthetic drugs that directly modify ionic exchange across myocardial cell membranes. However, there may be less direct ways of reducing the severity of such arrhythmias. These depend on modulating the release, or cellular effects, of biochemical and metabolic factors that themselves influence sarcolemmal ionic flux. Thus, such ischaemia-induced arrhythmias may result in part from the release of endogenous arrhythmogenic substances. A good example of an approach which attempts to modulate the effects of such an arrhythmogenic biochemical factor is the use of beta-adrenoceptor-blocking drugs to antagonize the effects of noradrenaline and adrenaline released during myocardial ischaemia. There are other less well appreciated possibilities. Examples include the ability of certain antagonists of both 5-HT and opioid peptides to reduce the severity of ischaemic arrhythmias in experimental animals (Coker et al. 1986; Fagbemi et al. 1982; Parratt and Sitsapesan 1986).

Keywords

Prostaglandin Ibuprofen Nifedipine Captopril Salicylate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ajioka M, Nagai S, Ogawa K, Satake T, Sugiyama S, Ozawa T (1986) The role of phospholipase in the genesis of reperfusion arrhythmia. J Electrocardiol 19: 165–172PubMedCrossRefGoogle Scholar
  2. Aksulu HE, Ercan ZS, Turker RK (1985) Further studies on the antiarrhythmic effect of iloprost. Arch Int Pharmacodyn Ther 277: 223–234PubMedGoogle Scholar
  3. Au TLS, Collins EA, Harris CJ, Walker MJA (1979) The action of prostaglandin I2 and prostaglandin E2 on arrhythmias produced by coronary occlusion in the rat and dog. Prostaglandins 18: 707–720PubMedCrossRefGoogle Scholar
  4. Au TLS, Harvie CJ, Johnston K, MacLeod BA, Walker MJA (1980) The effect of prostaglandin infusions on arrhythmic and other responses to coronary artery ligation. In: Förster, W (ed) Prostaglandins and thromboxanes. Fischer, Jena, pp 37–53Google Scholar
  5. Beamish RE, Dhillon KS, Singal PK, Dhalla NS (1981) Protective effect of sulfinpyrazone against catecholamine metabolite adrenochrome-induced arrhythmias. Am Heart J 102: 149–152PubMedCrossRefGoogle Scholar
  6. Benditt DG, Grant AO, Hutchison ABS, Strauss HC (1980) Electrophysiological effects of sulfinpyrazone on canine cardiac Purkinje fibers. Can J Physiol Pharmacol 58: 738–742PubMedCrossRefGoogle Scholar
  7. Bertha BG, Folts JD (1984) Inhibition of epinephrine-exacerbated coronary thrombus formation by prostacyclin in the dog. J Lab Clin Med 103: 204–214PubMedGoogle Scholar
  8. Boachie-Ansah G, Kane KA, Parratt JR (1986) Effects of adenosine, ATP and noradrenaline on normal and mildly “ischaemic” sheep cardiac Purkinje action potentials. Br J Pharmacol 88: 309PGoogle Scholar
  9. Brandt R, Nowak J, Sonnenfeld T (1984) Prostaglandin formation from exogenous precursor in homogenates of human cardiac tissue. Basic Res Cardiol 79: 135–141PubMedCrossRefGoogle Scholar
  10. Brembilla-Perrot B, Terrier De La Chaise A, Clozel JP, Cherrier F, Faivre G (1985) Proarrhythmic and antiarrhythmic effects of intravenous prostacyclin in man. Eur Heart J 6: 609–614PubMedGoogle Scholar
  11. Brunner L, Stepanek J, Brunner H (1980) Reduction of mortality by sulfinpyrazone after experimental myocardial infarction in the rat. J Pharm Pharmacol 32: 714–715PubMedCrossRefGoogle Scholar
  12. Burke SE, Antonaccio MJ, Lefer AM (1982) Lack of thromboxane A2 involvement in the arrhythmias occurring during acute myocardial ischaemia in dogs. Basic Res Cardiol 77: 411–422PubMedCrossRefGoogle Scholar
  13. Cairns JA, Gent M, Singer J, Finnie K, Froggatt GM, Holder DA, Jablonsky G, Kostuk WJ, Melendez LJ, Myres MG, Sackett DL, Sealey BJ, Tanser PH (1985) Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med 313: 1369–1375PubMedCrossRefGoogle Scholar
  14. Chamone DAF, van Damme B, Carreras LO, Vermylen J (1981) Increased release of vascular prostacyclin-like activity after long-term treatment of diabetic rats with Bay g6575. Haemostasis 10: 297–303PubMedGoogle Scholar
  15. Clark C, Foreman MI, Kane KA, McDonald FM, Parratt JR (1980) Coronary artery ligation in anaesthetised rats as a method of the production of experimental dysrhythmias and for the determination of infarct size. J Pharmacol Methods 76: 504–506Google Scholar
  16. Cohen I, Noble D, Ohba M, Ojeda C (1979) The interaction of ouabain and salicylate on sheep cardiac muscle. J Physiol (Lond) 297: 187–205Google Scholar
  17. Coker SJ (1982) Early arrhythmias arising from acute myocardial ischaemia; possible involvement of prostaglandins and thromboxanes. In: Parratt JR (ed) Early arrhythmias resulting from myocardial ischaemia. Oxford University Press, New York, pp 219–237Google Scholar
  18. Coker SJ (1984) Further evidence that thromboxane exacerbates arrhythmias: effects of UK38485 during coronary artery occlusion and reperfusion in anaesthetized greyhounds. J Mol Cell Cardiol 16: 633–641PubMedCrossRefGoogle Scholar
  19. Coker SJ, Parratt JR (1981) The effects of prostaglandins E2, F2 α, prostacyclin, flurbiprofen and aspirin on arrhythmias resulting from coronary artery ligation in anaesthetized rats. Br J Pharmacol 74: 155–159PubMedGoogle Scholar
  20. Coker SJ, Parratt JR (1983 a) Effects of dazoxiben on arrhythmias and ventricular fibrillation induced by coronary artery occlusion and reperfusion in anaesthetised greyhounds. Br J Clin Pharmacol 15: 87S–95SGoogle Scholar
  21. Coker SJ, Parratt JR (1983 b) Prostacyclin-antiarrhythmic or arrhythmogenic? Comparison of the effects of intravenous and intracoronary prostacyclin and ZK36374 during coronary artery occlusion and reperfusion in anaesthetised greyhounds. J Cardiovasc Pharmacol 5: 557–567PubMedCrossRefGoogle Scholar
  22. Coker SJ, Parratt JR (1983 c) Nifedipine reduces arrhythmias but does not alter prostanoid release during coronary artery occlusion and reperfusion in anaesthetised greyhounds. J Cardiovasc Pharmacol 5: 406–417PubMedCrossRefGoogle Scholar
  23. Coker SJ, Parratt JR (1984 a) The effects of nafazatrom on arrhythmias and prostanoid release during coronary artery occlusion and reperfusion in anaesthetized greyhounds. J Mol Cell Cardiol 16: 43–52PubMedCrossRefGoogle Scholar
  24. Coker SJ, Parratt JR ( 1984 b) Aspirin in the early stages of myocardial infarction. In: Royal Society of Medicine International Congress and Symposium Series 71: 71–75Google Scholar
  25. Coker SJ, Parratt JR (1985a) Relationships between the severity of myocardial ischaemia, reperfusion-induced ventricular fibrillation, and the late administration of dazmegrel or nifedipine. J Cardiovasc Pharmacol 7: 327–334PubMedCrossRefGoogle Scholar
  26. Coker SJ, Parratt JR (1985b) AH23848, a thromboxane antagonist, suppresses ischaemia and reperfusion-induced arrhythmias in anaesthetized greyhounds. Br J Pharmacol 86: 259–264PubMedGoogle Scholar
  27. Coker SJ, Parratt JR (1985c) Does inhibition of thromboxane synthesis account for the antiarrhythmic activity of aspirin in canine myocardial ischaemia and reperfusion? J Mol Cell Cardiol 17 [Suppl 3] Abstract 109Google Scholar
  28. Coker SJ, Marshall RJ, Parratt JR, Zeitlin IJ (1981a) Does the local myocardial release of prostaglandin E2 or F2 α contribute to the early consequences of acute myocardial ischaemia? J Mol Cell Cardiol 13: 425–434PubMedCrossRefGoogle Scholar
  29. Coker SJ, Ledingham IMcA, Parratt JR, Zeitlin IJ (1981b) Thromboxane B2 and 6-keto PGF1α release into coronary venous blood: effect of coronary artery occlusion. J Physiol (Lond) 316: 12 PGoogle Scholar
  30. Coker SJ, Parratt JR, Ledingham IMcA, Zeitlin IJ (1981c) Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias. Nature 291: 323–324PubMedCrossRefGoogle Scholar
  31. Coker SJ, Ledingham IMcA, Parratt JR, Zeitlin IJ (1981 d) Aspirin inhibits the early myocardial release of thromboxane B2 and ventricular ectopic activity following coronary artery occlusion in dogs. Br J Pharmacol 72: 593–595PubMedGoogle Scholar
  32. Coker SJ, Parratt JR, Ledingham IMcA, Zeitlin IJ (1982) Evidence that thromboxane contributes to ventricular fibrillation induced by reperfusion of the ischaemic myocardium. J Mol Cell Cardiol 14: 438–485CrossRefGoogle Scholar
  33. Coker SJ, Dean HG, Kane KA, Parratt JR (1986) The effects of 205–930, a 5-HT antagonist, on arrhythmias and catecholamine release during canine myocardial ischaemia and reperfusion. Eur J Pharmacol 127: 211–218PubMedCrossRefGoogle Scholar
  34. Corr PB, Sobel BE (1982) Amphiphilic lipid metabolism and ventricular arrhythmias. In: Parratt JR (ed) Early arrhythmias resulting from myocardial ischaemia. Oxford University Press, New York, pp 199–218Google Scholar
  35. Davenport N, Goldstein RE, Capurro N, Lipson LC, Bonow RO, Shulman NR, Epstein SE (1981) Sulfinpyrazone and aspirin increase epicardial coronary collateral flow in dogs. Am J Cardiol 47: 848–854PubMedCrossRefGoogle Scholar
  36. De Langen CD J, van Gilst WH, Wesseling H (1985) Sustained protection by iloprost of the porcine heart in the acute and chronic phases of myocardial infarction. J Cardiovasc Pharmacol 7: 924–928PubMedCrossRefGoogle Scholar
  37. Dix RK, Kelliher GJ, Jurkiewicz N, Lawrence T (1979) The influence of prostacyclin in coronary occlusion induced arrhythmia in cats. Prostaglandins Med 3: 173–184PubMedCrossRefGoogle Scholar
  38. Dix RK, Kelliher GJ, Jurkiewicz N, Smith JB (1982) Effect of sulfinpyrazone on ventricular arrhythmia, prostaglandin synthesis, and catecholamine release following coronary artery occlusion in the cat. J Cardiovasc Pharmacol 4: 1068–1076PubMedCrossRefGoogle Scholar
  39. Düsing R, Scherag R, Landsberg G, Glanzer K, Kramer HJ (1983) The converting enzyme inhibitor captopril stimulates prostacyclin synthesis by isolated rat aorta. Eur J Pharmacol 91: 501–504PubMedCrossRefGoogle Scholar
  40. Fagbemi SO (1984) The effect of aspirin, indomethacin and sodium meclofenamate on coronary artery ligation arrhythmias in anaesthetized rats. Eur J Pharmacol 97: 283–287PubMedCrossRefGoogle Scholar
  41. Fagbemi O (1985) The effects of the combined administration of β-adrenoceptor antagonists and non-steroidal anti-inflammatory drugs on ligation-induced arrhythmias in rats. Br J Pharmacol 85: 361–365PubMedGoogle Scholar
  42. Fagbemi O, Leprán I, Parratt JR, Szekeres L (1982) Naloxone inhibits early arrhythmias resulting from acute coronary ligation. Br J Pharmacol 76: 504–506PubMedGoogle Scholar
  43. Fiedler VB (1983 a) Reduction of myocardial infarction and dysrhythmic activity by nafazatrom in the conscious rat. Eur J Pharmacol 88:263–267PubMedCrossRefGoogle Scholar
  44. Fiedler VB (1983 b) The effects of oral nafazatrom (= BAY g6575) on canine coronary artery thrombosis and myocardial ischemia. Basic Res Cardiol 78:266–280PubMedCrossRefGoogle Scholar
  45. Fiedler VB (1984) Reduction of acute myocardial ischemia in rabbit hearts by nafazatrom. J Cardiovasc Pharmacol 6: 318–324PubMedCrossRefGoogle Scholar
  46. Fiedler VB (1985) Failure of nafazatrom to reduce infarct size and arrhythmias in a porcine model of acute coronary occlusion. Eur J Pharmacol 114: 189–196PubMedCrossRefGoogle Scholar
  47. Fiedler VB, Mardin M (1985 a) Influence of prostacyclin on coronary thrombosis and myocardial ischemia in conscious canine experiments. Arch Int Pharmacodyn Ther 278: 114–127PubMedGoogle Scholar
  48. Fiedler VB, Mardin M (1985b) Effects of nafazatrom and indomethacin on experimental myocardial ischemia in the anesthetized dog. J Cardiovasc Pharmacol 7: 983–989PubMedCrossRefGoogle Scholar
  49. Fiedler VB, Mardin M (1986) Prostacyclin prevents ventricular fibrillation in a canine model of sudden cardiac death. Basic Res Cardiol 81: 40–53PubMedCrossRefGoogle Scholar
  50. Fiedler VB, Kettenbach B, Gobel H, Nitz R-E (1985 a) Protection by carbochromen and molsidomine against arrhythmias occurring during coronary artery occlusion and reperfusion in dogs. J Cardiovasc Pharmacol 7: 964–970PubMedCrossRefGoogle Scholar
  51. Fiedler VB, Mardin M, Perzborn E, Griitzmann R (1985 b) The effects of nafazatrom in an acute occlusion-reperfusion model of canine myocardial injury. Naunyn-Schmiedebergs Arch Pharmacol 331: 267–274PubMedCrossRefGoogle Scholar
  52. Folts JD, Crowell EB, Rowe GG (1976) Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 54: 365–370PubMedGoogle Scholar
  53. Folts JD, Gallagher K, Rowe GG (1982) Blood flow reductions in stenosed canine coronary arteries: vasospasm or platelet aggregation? Circulation 65: 248–255PubMedCrossRefGoogle Scholar
  54. Förster W (1976) Prostaglandins and prostaglandin precursors as endogenous antiarrhythmic principles of the heart. Acta Biol Med Germ 35: 1101–1112PubMedGoogle Scholar
  55. Förster W, Mest H-J, Mentz P (1973) The influence of PGF2 α on experimental arrhythmias. Prostaglandins 3: 895–904PubMedCrossRefGoogle Scholar
  56. Hammon JW, Oates JA (1986) Interaction of platelets with the vessel wall in the pathophysiology of sudden cardiac death. Circulation 73: 224–226PubMedCrossRefGoogle Scholar
  57. Hashimoto K, Shibuya T, Imai S (1983) Effects of prostaglandins on late coronary ligation arrhythmias in the dog. Jpn J Pharmacol 33: 1035–1039PubMedCrossRefGoogle Scholar
  58. Henriksson P, Wennmalm A, Edhag O, Vesterqvist O, Green K (1986) In vivo production of prostacyclin and thromboxane in patients with acute myocardial infarction. Br Heart J 55: 543–548PubMedCrossRefGoogle Scholar
  59. Herbaczynska-Cedro K, Gordon-Majszak W (1986) Attenuation by prostacyclin of adrenaline-stimulated lipid peroxidation in the myocardium. Pharmacol Res Commun 81: 321–332CrossRefGoogle Scholar
  60. Hirche HJ, Friedrich R, Kebbel V, McDonald F, Zylka V (1982) Early arrhythmias, myocardial extracellular potassium and pH. In: Parratt JR (ed), Early arrhythmias resulting from myocardial ischaemia. Oxford University Press, New York, pp 113–124Google Scholar
  61. Honn KV, Dunn JR (1982) Nafazatrom (Bag g6575) inhibition of tumor cell lipoxygenase activity and cellular proliferation. FEBS Lett 139: 65–68PubMedCrossRefGoogle Scholar
  62. Johnson GJ, Heckel R, Leis LA, Franciosa J (1981) Effect of inhibition of platelet function with carbenicillin or aspirin on experimental canine sudden death. J Lab Clin Med 98: 660–672PubMedGoogle Scholar
  63. Johnston KM, MacLeod BA, Walker MJA (1983) Effects of aspirin and prostacyclin on arrhythmias resulting from coronary artery ligation and on infarct size. Br J Pharmacol 78: 29–37PubMedGoogle Scholar
  64. Jouve R, Puddu PE, Langlet F, Guillen J-C, Gautier T, Cano J-P, Serradimigni A (1985) Epoprostenol (PGI2) prevents postischemic ventricular fibrillation and improves outcome in a canine model of sudden death. J Pharmacol 16: 139 - 157PubMedGoogle Scholar
  65. Kahlen T, Schrör K (1982) Mepindolol protection of prostacyclin formation. Subsequent increase in arachidonic acid-induced prostacyclin release in isolated guinea pig heart. Eur J Pharmacol 82: 81–84PubMedCrossRefGoogle Scholar
  66. Kecskemeti V (1980) Effects of prostacyclin-sodium and prostacyclin-ethyl ester on cardiac transmembrane potentials. In: Fischer, Förster W (ed) Prostaglandins and thromboxanes. Jena, pp 107–109Google Scholar
  67. Kecskemeti V, Kelemen K, Knoll J (1973) Effect of prostaglandin Ex on the cardiac transmembrane potentials. Eur J Pharmacol 24: 289–295PubMedCrossRefGoogle Scholar
  68. Kecskemeti V, Kelemen K, Knoll J (1978) Comparative effects of prostaglandin F2 and A2 on the cardiac transmembrane potentials. Acta Biol Med Germ 37: 821–824PubMedGoogle Scholar
  69. Kelliher GJ, Glenn TM (1973) Effect of PGE1 on ouabain induced arrhythmias. Eur J Pharmacol 24: 410–416PubMedCrossRefGoogle Scholar
  70. Kelliher GJ, Dix RK, Jurkiewicz N, Lawrence TL (1980) Effect of sulfinpyrazone on arrhythmia and death following coronary occlusion in cats. In: McGregor M, Mustard JF, Oliver MF, Sherry S (eds) Cardiovascular actions of sulfinpyrazone: basic and clinical research. Symposium Specialists, Miami, pp 193–209Google Scholar
  71. Kowey PR, Verrier RL, Lown B (1982) Effects of prostacyclin (PGI2) on vulnerability to ventricular fibrillation in the normal and ischemic canine heart. Eur J Pharmacol 80: 83–91PubMedCrossRefGoogle Scholar
  72. Kowey PR, Verrier RL, Lown B, Handin RI (1983) Influence of intracoronary platelet aggregation on ventricular electrical properties during partial coronary artery stenosis. Am J Cardiol 51: 596–602PubMedCrossRefGoogle Scholar
  73. Kramer JB, Davis AG, Dean R, McCluskey ER, Needleman P, Corr PB (1985) Thromboxane A2 does not contribute to arrhythmogenesis during evolving canine myocardial infarction. J Cardiovasc Pharmacol 7: 1069–1076PubMedCrossRefGoogle Scholar
  74. Leprán I, Nemecz GY, Koltai M, Szekeres L (1981a) Effect of a linoleic acid-rich diet on the acute phase of coronary occlusion in conscious rats: influence of indomethacin and aspirin. J Cardiovasc Pharmacol 3: 847–853PubMedCrossRefGoogle Scholar
  75. Leprán I, Koltai M, Szekeres L (1981b) Effect of non-steroidal anti-inflammatory drugs in experimental myocardial infarction in rats. Eur J Pharmacol 69: 235–238PubMedCrossRefGoogle Scholar
  76. Lewis HD, Davis JW, Archibald DG (1983) Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration co-operations study. N Engl J Med 309: 396–403PubMedCrossRefGoogle Scholar
  77. Livio M, Villa S, De Gaetano G (1980) Long-lasting inhibition of platelet prostaglandin but normal vascular prostacyclin generation following sulphinpyrazone administration to rats. J Pharm Pharmacol 32: 718–719PubMedCrossRefGoogle Scholar
  78. Löbel P, Schrör K (1985) Selective stimulation of coronary vascular PGI2 but not of platelet thromboxane formation by defibrotide in the platelet perfused heart. Naunyn-Schmiedebergs Arch Pharmacol 331: 125–130PubMedCrossRefGoogle Scholar
  79. Madan BR, Gupta RS, Madan V (1974) Actions of prostaglandins E1, E2, F2 α in ouabain-induced arrhythmia and maximal electroshock seizures. Indian J Med Res 62: 1647–1651PubMedGoogle Scholar
  80. May GS, Eberlein KA, Furberg CD, Passamani ER, De Mays DL (1982) Secondary prevention after myocardial infarction: a review of long-term trials. Prog Cardiovasc Dis 24: 331–352PubMedCrossRefGoogle Scholar
  81. McDonald BR, Jones PBB, Russell RGG, Radford J, Martin JF (1983) Urinary 6-oxo prostaglandin F1α in myocardial infarction. Br Med J 287: 727CrossRefGoogle Scholar
  82. McLennan PL, Abeywardena MY, Charnock JS (1985) Influence of dietary lipids on arrhythmias and infarction after coronary artery ligation in rats. Can J Physiol Pharmacol 63: 1411–1417PubMedCrossRefGoogle Scholar
  83. Mehta J, Mehta P (1985) Prostacyclin and thromboxane A2 production by human cardiac atrial tissues. Am Heart J 109: 1–3PubMedCrossRefGoogle Scholar
  84. Mehta J, Mehta P, Ostrowski N (1986) Calcium blocker diltiazem inhibits platelet activation and stimulates vascular prostacyclin synthesis. Am J Med Sci 291: 20–24PubMedCrossRefGoogle Scholar
  85. Mest H-J, Förster W (1978) The antiarrhythmic action of prostacyclin (PGI2) on aconitine induced arrhythmia in rats. Acta Biol Med Germ 37: 827–828PubMedGoogle Scholar
  86. Michael LH, Hunt JR, Lewis RM, Entman ML (1986) Myocardial ischemia:platelet and thromboxane concentrations in cardiac lymph and the effects of ibuprofen and prostacyclin. Circ Res 59: 49–55PubMedGoogle Scholar
  87. Moschos CB, Lahiri K, Peter A, Jesrani MU, Regan TJ (1972) Effect of aspirin upon experimental coronary and non-coronary thrombosis and arrhythmia. Am Heart J 84: 525–530PubMedCrossRefGoogle Scholar
  88. Moschos MD, Lahiri K, Lyons M, Weisse AB, Oldewurtel HA, Regan TJ (1973) Relation of microcirculatory thrombosis to thrombus in the proximal coronary artery: effect of aspirin, dipyridamole, and thrombolysis. Am Heart J 86: 61–68PubMedCrossRefGoogle Scholar
  89. Moschos CB, Haider B, DeLa Cruz C, Lyons MM, Regan TJ (1978) Antiarrhythmic effects of aspirin during nonthrombotic coronary occlusion. Circulation 57: 681–684PubMedGoogle Scholar
  90. Moschos CB, Haider B, Escobinas AJ, Gandhi A, Regan TJ (1980aa) Chronic use of aspirin versus indomethacin during non-thrombotic myocardial ischemia: effects on survival. Am Heart J 100: 647–652PubMedCrossRefGoogle Scholar
  91. Moschos CB, Escobinas AJ, Jorgensen OB (1980b) Effects of sulfinpyrazone in ischemic myocardium. In: McGregor M, Mustard JF, Oliver MF, Sherry S (eds) Symposia Specialists, Miami, pp 175–187Google Scholar
  92. Müller B, Schneider J, Hennies HH, Flohe L (1984) Cardioprotective action of the new stable epoprostenol analogue CG 4203 in rat models of cardiac hypoxia and ischemia. Arzneimittelforschung 34: 1506–1509PubMedGoogle Scholar
  93. Nayler WG, Purchase M, Dusting GJ (1984) Effect of prostacyclin infusion during low-flow ischaemia in the isolated perfused rat heart. Basic Res Cardiol 79: 125–134PubMedCrossRefGoogle Scholar
  94. Needleman SW, Spector AA, Hoak JC (1982) Enrichment of human platelet phospholipids with linoleic acid diminishes thromboxane release. Prostaglandins 24: 607–622PubMedCrossRefGoogle Scholar
  95. O’Connor KM, Friehling TD, Kelliher GJ, MacNab MW, Wetstein L, Kowey PR (1986) Effect of thromboxane synthetase inhibition on vulnerability to ventricular arrhythmia following coronary occlusion. Am Heart J 111: 683–688PubMedCrossRefGoogle Scholar
  96. Ohnishi H, Kosuzume H, Hayashi Y, Yamaguchi K, Suzuki Y, Itoh R (1981) Effects of trapidil on thromboxane A2-induced aggregation of platelets, ischemic changes in heart and biosynthesis of thromboxane A2. Prostaglandins and Medicine 6: 269–281PubMedCrossRefGoogle Scholar
  97. Otani H, Engelman RM, Breyer RH, Rousou JA, Lemeshow S, Das DK (1986) Mepacrine, a phospholipase inhibitor. J Thorac Cardiovasc Surg 92: 247–254PubMedGoogle Scholar
  98. Parratt JR, Coker SJ (1980) The significance of prostaglandin and thromboxane release in acute myocardial ischaemia. In: Forster W (ed) Prostaglandins and Thromboxanes Fischer, Jena, pp 21–25Google Scholar
  99. Parratt JR, Sitsapesan R (1986) Stereospeciflc antiarrhythmic effect of opioid receptor antagonists in myocardial ischaemia. Br J Pharmacol 87: 621–622PubMedGoogle Scholar
  100. Parratt JR, Wainwright CL (1986 a) Ventricular arrhythmias induced by local injections of vasoconstrictors following coronary occlusion. Br J Pharmacol 88: 397 PGoogle Scholar
  101. Parratt JR, Wainwright CL (1986b) The effects of the thromboxane antagonist BM13.177 on ischaemia and reperfusion induced arrhythmias in dogs. Br J Pharmacol 88: 291 PGoogle Scholar
  102. Parratt JR, Coker SJ, Wainwright CL (1987) Eicosanoids and susceptibility to ventricular arrhythmias during myocardial ischaemia and reperfusion. J Mol Cell Cardiol 19, Suppl’V, 55–66PubMedCrossRefGoogle Scholar
  103. Povalski HJ, Olson R, Kopia S, Furness P (1980) Comparative effects of sulfinpyra-zone and aspirin in the coronary occlusion-reperfusion dog model. In: McGregor M, Mustard JF, Oliver MF, Sherry S (eds) Cardiovascular actions of sulfinpyrazone. Symposium Specialists, Miami, pp 153–171Google Scholar
  104. Purchase M, Dusting GJ, Li DMF, Read MA (1986) Physiological concentrations of epinephrine potentiate thromboxane A2 release from platelets in the rat isolated heart. Circ Res 58: 172–176PubMedGoogle Scholar
  105. Rabkin SW, Ohmae M (1980) Effect of sulfinpyrazone on adriamycin induced acute cardiotoxic arrhythmias in rabbits. Pharmacol Res Commun 12: 196–204CrossRefGoogle Scholar
  106. Ribeiro LGT, Brandon TA, Hopkins DG, Reduto LA, Taylor AA, Miller RR (1981) Prostacyclin in experimental myocardial ischaemia: effects on hemodynamics, regional myocardial blood flow, infarct size and mortality. Am J Cardiol 47: 835–840PubMedCrossRefGoogle Scholar
  107. Ruf W, McNamara JJ, Suehiro A, Suehiro G, Wickline S (1980) Platelet trapping in myocardial infarct in baboons: therapeutic effect of aspirin. Am J Cardiol 46: 405–412PubMedCrossRefGoogle Scholar
  108. Sakanashi M, Yoshikawa Y, Akiyoshi R, Itoh C, Kitamura Y, Niho T, Ohnishi H (1983) Possible antiarrhythmic activities of trapidil. Arzneimittelforschung 33: 215–217PubMedGoogle Scholar
  109. Schrör K, Thiemermann C (1986) Treatment of acute myocardial ischaemia with a selective antagonist of thromboxane receptors (BM 13.177). Br J Pharmacol 87: 631–637PubMedGoogle Scholar
  110. Schrör K, Addicks K, Darius H, Ohlendorf R, Rosen P (1981a) PGI2 inhibits ischemia- induced platelet activation and prevents myocardial damage by inhibition of catecholamine release from adrenergic nerve terminals. Evidence for cAMP as common denominator. Thromb Res 21: 175–180PubMedCrossRefGoogle Scholar
  111. Schrör K, Ohlendorf R, Darius H (1981b) Beneficial effects of a new carbacyclin derivative, ZK 36 374, in acute myocardial ischemia. J Pharmacol Exp Ther 219: 243–249PubMedGoogle Scholar
  112. Schrör K, Darius H, Ohlendorf R, Matzky R, Klaus W (1982) Dissociation of antiplatelet effects from myocardial cytoprotective activity during acute myocardial ischemia in cats by a new carbacyclin derivative (ZK 36375). J Cardiovasc Pharmacol 4: 554–561PubMedGoogle Scholar
  113. Seuter F, Busse WD, Meng K, Hoffmeister F, Moller E, Horstmann H (1979) The antithrombotic activity of BAY g6575. Arzneimittelforschung 29: 54–59PubMedGoogle Scholar
  114. Shea MJ, Murtagh JJ, Jolly SR, Abrams GD, Pitt B, Lucchesi BR (1984) Beneficial effects of nafazatrom on ischemic reperfused myocardium. Eur J Pharmacol 102: 63–70PubMedCrossRefGoogle Scholar
  115. Smith EF, Gallenkämper W, Beckmann R, Thomsen T, Mannesmann G, Schrör K (1984) Early and late administration of a PGI2-analogue, ZK 36374 (iloprost): effects on myocardial preservation, collateral blood flow and infarct size. Cardiovasc Res 18: 163–173PubMedCrossRefGoogle Scholar
  116. Somberg JC, Bounous H, Cagin N, Anagnostopoulos L, Levitt B (1977) The influence of prostaglandins E1 and E2 on ouabain cardiotoxicity in the cat. J Pharmacol Exp Ther 203: 480–484PubMedGoogle Scholar
  117. Spector AA, Hoak C-L, Fry GL, Denning EM, Stoll LL, Smith JB (1980) Effect of fatty acid modification on prostacyclin production by cultured human endothelium cells. J Clin Invest 65: 1003–1012PubMedCrossRefGoogle Scholar
  118. Starnes VA, Primm RK, Woosley RL, Oates JA, Hammon JW (1982) Administration of prostacyclin prevents ventricular fibrillation following coronary occlusion in conscious dogs. J Cardiovasc Pharmacol 4: 765–769PubMedCrossRefGoogle Scholar
  119. Stäubli RC, Baur HR, Althaus U, Pop HP, Wehrli HP, Gurtner HP (1984) Influence of sulfinpyrazone on infarct size, hemodynamics, and arrhythmia following coronary occlusion in the pig. J Cardiovasc Pharmacol 6: 829–832PubMedCrossRefGoogle Scholar
  120. Szekeres L, Lepran I, Boros E, Takats I, Koltai M (1982) The effect of non-steroid anti-inflammatory drugs and of linoleic acid-rich diet on early arrhythmias resulting from myocardial ischaemia. In: Parratt JR (ed) Early arrhythmias resulting from myocardial ischaemia. Oxford University Press, New York, pp 239–249Google Scholar
  121. Tada M, Kuzuya T, Michitoshi I, Kodama K, Mishima M, Yamada M, Inui M, Abe H (1981) Elevation of thromboxane B2 levels in patients with classic and variant angina pectoris. Circulation 64: 1107–1115PubMedCrossRefGoogle Scholar
  122. Tada M, Hoshida S, Kuzuya T, Michitoshi I, Minamino T, Abe H (1985) Augmented thromboxane A2 generation and efficacy of its blockade in acute myocardial infarction. Int J Cardiol 8: 301–312PubMedCrossRefGoogle Scholar
  123. Thiemermann C, Steinhagen-Thiessen E, Schrör K (1984) Inhibition of oxygen-centered free radical formation by the stable prostacyclin-mimetic iloprost (ZK 36374) in acute myocardial ischaemia. J Cardiovasc Pharmacol 6: 365–366PubMedCrossRefGoogle Scholar
  124. Thiemermann C, Löbel P, Schrör K (1985) Usefulness of defibrotide in protecting is-chemic myocardium from early reperfusion damage. Am J Cardiol 56: 978–982PubMedCrossRefGoogle Scholar
  125. Trachte GJ (1986) Thromboxane agonist (U46619) potentiates norepinephrine efflux from adrenergic nerves. J Pharmacol Exp Ther 237: 473–477PubMedGoogle Scholar
  126. van Gilst WH, Terpstra JA, de Langen CD J (1985) Ventricular arrhythmias and purine loss upon reperfusion of ischemic myocardium: comparison of ZK 36374 and diltiazem. In: Schrör K, (ed) Prostaglandins and other eicosanoids in the cardiovascular system. Karger, Basel, pp 207–212Google Scholar
  127. Vermylen J, Chamone DAF, Verstraete M (1979) Stimulation of prostacyclin release from vessel wall by Bay g6575, an antithrombotic compound. Lancet 1: 518–520PubMedCrossRefGoogle Scholar
  128. Wenzel DG, Innis DJ (1983) Protection from arrhythmias of cultured heart cells by nonsteroid anti-inflammatory drugs. Pharmacol Res Commun 15: 167–172PubMedCrossRefGoogle Scholar
  129. Wong PY-K, Chao PH-W, McGiff JC (1982) Nafazatrom (Bay g-6575), an antithrombotic and antimetastatic agent, inhibits 15-hydroxyprostaglandin dehydrogenase. J Pharmacol Exp Ther 223: 757–780PubMedGoogle Scholar
  130. Zijlstra WG, Brunsting JR, Ten Hoor P, Vergrosen AJ (1972) Prostaglandin E1 and cardiac arrhythmia. Eur J Pharmacol 18: 392–395PubMedCrossRefGoogle Scholar
  131. Zylka V, Addicks K, Deutsch HJ, Friedrick R, Griebenow R, Hirche HJ (1981) The antiarrhythmic effect of prostacyclin (PGI2) in severe myocardial ischemia in the pig heart. Pflugers Arch 389: [Suppl R1]Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • J. R. Parratt

There are no affiliations available

Personalised recommendations